NCT06106529View on ClinicalTrials.gov

REDucing Hot FLASHes in Women Using Endocrine Therapy.

PHASE3RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

October 3, 2024

Primary Completion Date

January 1, 2029

Study Completion Date

January 1, 2029

Conditions
Breast CancerHot Flash Due to Medication
Interventions
DRUG

Oxybutynin

Oxybutynin 5 mg twice per day for 6 weeks

DRUG

Venlafaxine

Venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks

Trial Locations (1)

2625 AD

RECRUITING

Reinier de Graaf Gasthuis, Delft

All Listed Sponsors
lead

Reinier de Graaf Groep

OTHER